Armata Pharmaceuticals ARMP
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Armata Pharmaceuticals (ARMP)
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
Key Insights
Critical company metrics and information
Latest Closing Price
$2.023Market Cap
$73.20 MillionPrice-Earnings Ratio
-13.49Total Outstanding Shares
36.18 Million SharesTotal Employees
75Dividend
No dividendIPO Date
May 27, 1994SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
American Stock ExchangeType
Common StockHeadquarters
5005 mcconnell ave, Los angeles, CA, 90066Homepage
https://www.armatapharma.com
Historical Stock Splits
If you bought 1 share of ARMP before July 7, 2011, you'd have 10 shares today.
| Execution Date | Split Amount |
|---|---|
| April 25, 2017 | 1-for-10 (Reverse Split) |
| July 7, 2011 | 100-for-1 |
Cash Flow Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities | $-340,000 |
| Net Cash Flow | $-9.26 Million |
| Net Cash Flow From Financing Activities | $-61,000 |
| Net Cash Flow, Continuing | $-9.26 Million |
| Net Cash Flow From Financing Activities, Continuing | $-61,000 |
| Net Cash Flow From Operating Activities | $-8.86 Million |
Income Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Available To Common Stockholders, Basic | $-5.48 Million |
| Basic Average Shares | $36.18 Million |
| Basic Earnings Per Share | $-0.15 |
| Costs And Expenses | $12.73 Million |
| Revenues | $2.97 Million |
| Income/Loss From Continuing Operations Before Tax | $-5.48 Million |
Comprehensive Income
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $-5.48 Million |
| Comprehensive Income/Loss Attributable To Parent | $-5.48 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $0 |
Balance Sheet
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Intangible Assets | $10.26 Million |
| Accounts Payable | $1.81 Million |
| Liabilities | $149.21 Million |
| Equity | $-50.97 Million |
| Current Liabilities | $118.20 Million |
| Liabilities And Equity | $98.24 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Recent Headlines From The Web
Latest news, press releases, and media coverage about ARMP from trusted financial sources
â“’ 2025 Financhle. All Rights Reserved.